key: cord-0911817-blhf1v7z
authors: Legnani, Claudio; Dusi, Elisa
title: Novel pathogens, same old habits. A call for evidence-based research in the fight against COVID-19
date: 2021-01-18
journal: Infect Dis Now
DOI: 10.1016/j.idnow.2021.01.004
sha: 762d706e4f0aae00ce70d05b7be02dbadfdb7947
doc_id: 911817
cord_uid: blhf1v7z

nan

J o u r n a l P r e -p r o o f With the rapid spread of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1] , journals are receiving an increasing number of papers on the issue [2] .

Many of them are focused on how to improve patient management and therapeutic interventions, and a massive collective effort is being brought to bear by the scientific community to enhance currently available COVID-19 treatments, and ultimately to defeat SARS-CoV-2.

At present, no medicine or vaccine has been officially approved as treatment for COVID-19associated pathologies, and current disease management relies on infection prevention through social distancing and increased hygiene, and supportive care involving oxygen supplementation.

The race by the scientific community to find solutions has led to a spree in scientific publication, including many papers of poor quality.

Given the paucity of reliable data about this novel virus, the organization of studies with a high level of evidence can be signally challenging.

However, even and especially in this prolonged emergency situation, it should be borne in mind that the ongoing search for effective new drugs, suitable treatment protocols and preventive strategies requires appropriate and valid trials (i.e., prospective, randomised-controlled clinical studies, international multicenter studies)

In the absence of reliable data, premature affirmations from the scientific community about treatment efficacy should be foresworn, as they could lead to avoidable complications.

As an example, chloroquine and hydroxychloroquine have recently been put in the spotlight as potential game changers in COVID-19 prophylaxis and treatment [3, 4] . Without available data from randomized controlled trials evidence sufficient to justify recommendations, off-label use of hydroxychloroquine for COVID-19 patients has been promoted [4] .

Such incautious behaviour may entail improper use of drugs, causing harm due to side effects and overdose, and also resulting in drug shortages for patients requiring specific medications for chronic illnesses.

In addition to that, many publishers encourage projects that do not require extensive inquiry and evidence gathering. The growing burden of journals which fail to conduct peer review and have very poor scholarly quality is likely to contribute to the rise of low-quality papers.

Caution by public health professionals, world leaders, and scientific journal editors is called for.

Everyone involved in the war against COVID-19 should be made to understand that anecdotal reports with limited in vitro data can be detrimental to ongoing research and that only evidencebased, rigorous and high-quality clinical data should be taken into consideration.

In the absence of reputable evidence, our best choice as a scientific community is to adhere to current guidelines, express solidarity and, if our "expert opinion" may not be of help, exercise our right to uncomfortable silence.

A novel coronavirus outbreak of global health concern

A Bibliometric Analysis of COVID-19 Research Activity: A Call for Increased Output

Chloroquine or hydroxychloroquine for prophylaxis of COVID-19

Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)

The authors wish to thank Carolina Legnani for her precious help during the lockdown period.